Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Inclusion Criteria:

* Patients with histologically proven Stage IV and Stage III (with malignant pleural or pericardial effusion) squamous or adenocarcinoma carcinomas of the lung
* Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis
* No previous anticancer treatment for metastatic/advanced disease. Patients who received prior adjuvant chemotherapy are eligible if they have remained free of disease for at least 6 months after the completion of adjuvant therapy.
* Age above 18 years
* Performance status (ECOG) 0-2
* Life expectancy \>= 3 months
* Effective contraception for both male and female subjects if the risk of conception exists
* Adequate hematologic parameters (absolute neutrophil count \>= 1.5x109/L and platelets \>= 100x109/L), creatinine (GFR\>= 60ml/min) and total bilirubin \< 1.5 times the upper limit of normal; aspartate and alanine aminotransferase \< 2,5 times the upper limit of normal
* All patients will have to sign written informed consent in order to participate in the study

Exclusion Criteria:

* Patients with non-squamous tumors who have no contradiction for administration of bevacizumab
* Active infection or malnutrition (loss of more than 20% of the body weight)
* Known hypersensitivity reaction to any of the component of the treatment
* Concurrent or previous chronic systemic immune therapy
* Pregnancy (absence to be confirmed by ß-HCG test) or lactation period
* Known alcohol/drug abuse
* Legal incapacity or limited legal capacity
* Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent
* A second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma
* Previous radiotherapy to the target lesions. Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields
* Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of uncontrolled arrhythmia